Laidlaw downgraded Evoke Pharma (EVOK) to Hold from Buy after QOL Medical announced a deal to acquire Evoke for $11.00 per share in cash at closing.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVOK: